O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-4.89%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.86B
AUM Growth
+$9.86B
(-7.5%)
Cap. Flow
+$313M
Cap. Flow
% of AUM
3.17%
Top 10 Holdings %
Top 10 Hldgs %
30.57%
Holding
177
New
20
Increased
25
Reduced
24
Closed
19
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$127M |
| 2 |
Neuropace
NPCE
|
$95.5M |
| 3 |
Janux Therapeutics
JANX
|
$86.5M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$70.2M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$59.7M |
Top Sells
| 1 |
Haemonetics
HAE
|
$94.6M |
| 2 |
Adverum Biotechnologies
ADVM
|
$54.2M |
| 3 |
AbCellera Biologics
ABCL
|
$43.5M |
| 4 |
Molina Healthcare
MOH
|
$38M |
| 5 |
Progyny
PGNY
|
$33M |
Sector Composition
| 1 | Healthcare | 95.36% |
| 2 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $498M | 5.04% | 6,044,266 -142,041 | -2% | -$11.7M |
|
2
Bristol-Myers Squibb
BMY
$96B
| $302M | 3.05% | 4,515,400 | – | – |
|
3
Edgewise Therapeutics
EWTX
$1.51B
| $297M | 3.01% | 13,944,680 | – | – |
|
4
Boston Scientific
BSX
$156B
| $296M | 2.99% | 6,920,600 | – | – |
|
5
Merck
MRK
$210B
| $290M | 2.94% | 3,732,400 | – | – |
|
6
Prelude Therapeutics
PRLD
$68.5M
| $287M | 2.91% | 10,039,691 | – | – |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $274M | 2.77% | 2,922,155 -222,200 | -7% | -$20.8M |
|
8
ARS Pharmaceuticals
SPRY
$1.15B
| $270M | 2.73% | 8,740,887 | – | – |
|
9
PMV Pharmaceuticals
PMVP
$74.2M
| $250M | 2.53% | 7,330,423 | – | – |
|
10
Natera
NTRA
$23.1B
| $234M | 2.36% | 2,057,800 -138,100 | -6% | -$15.7M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $215M | 2.17% | 1,065,400 -70,500 | -6% | -$14.2M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $204M | 2.07% | 1,264,200 +43,000 | +4% | +$6.95M |
|
|
TPTX
13
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $184M | 1.86% | 2,361,327 | – | – |
|
14
Iovance Biotherapeutics
IOVA
$807M
| $173M | 1.75% | 6,645,100 | – | – |
|
15
Arcutis Biotherapeutics
ARQT
$1.86B
| $166M | 1.68% | 6,073,850 | – | – |
|
16
UnitedHealth
UNH
$281B
| $156M | 1.58% | 389,700 -13,300 | -3% | -$5.33M |
|
17
Guardant Health
GH
$8.41B
| $152M | 1.54% | 1,227,400 +250,000 | +26% | +$31M |
|
18
Humana
HUM
$36.5B
| $148M | 1.5% | 335,000 +21,400 | +7% | +$9.47M |
|
|
19
AbCellera Biologics
ABCL
$1.25B
| $137M | 1.38% | 6,223,019 -1,977,749 | -24% | -$43.5M |
|
20
AbbVie
ABBV
$372B
| $132M | 1.33% | 1,167,500 -45,700 | -4% | -$5.15M |
|
21
Intuitive Surgical
ISRG
$170B
| $128M | 1.3% | 139,600 | – | – |
|
22
Elevance Health
ELV
$71.8B
| $128M | 1.3% | 335,700 +49,100 | +17% | +$18.7M |
|
23
DexCom
DXCM
$29.5B
| $127M | 1.28% | 297,400 | – | – |
|
|
24
SPDR S&P Biotech ETF
XBI
$5.07B
| $127M | 1.28% | +935,700 | New | +$127M |
|
|
DCPH
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $121M | 1.22% | 3,297,301 +1,916,401 | +139% | +$70.2M |
|